Our achievements. Our accomplishments. Our impact.

Federal Government Invests in Stem Cell Research


  • Commercialization

    The Stem Cell Network’s catalysis of commercialization of stem cell research has led to 399 patent applications, 60 issued patents, 43 licenses granted, the growth or launch of 11 start-up biotechnology companies and the establishment of a new Centre for the Commercialization of Regenerative Medicine (CCRM) to develop a strong industry presence in several emerging technology areas likely to be crucial to the future delivery of stem cell-based therapies.


  • Stem Cell Genomics

    SCN’s Gene Expression Project was made possible through the Network’s collaborative approach to research, and the Project’s use of a single centre to undertake a standardized analysis of hundreds of stem cell lines allowed for the creation of pertinent data and meta-data to be accessed by thousands of researchers around the world.


  • Patient Engagement

    The Stem Cell Network engaged world-leading researchers and ethicists to provide Canadians with credible and accessible information on the latest advancements in stem cell research.


  • Evidence-Based Policy Making

    When the Stem Cell Network launched in 2001, its most pressing goal was to address the policy vacuum that was constraining stem cell research in Canada. SCN and its members provided credible, research-based evidence and recommendations that were critical in the development of Canada’s regulatory landscape for stem cell research.


  • Establishing a Community

    By prioritizing multidisciplinary research partnerships among stem cell researchers across Canada, the Stem Cell Network integrated the country’s previously fractured landscape into a comprehensive and globally respected research community.


  • Blood Stem Cell Expansion

    Over more than a decade of targeted funding, the Stem Cell Network harnessed the strength of world-leading Canadian researchers to develop technologies to increase quantities of blood stem cells for expanded therapeutic use and to overcome a significant hurdle in the delivery of cell-based treatments to patients.